{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014088","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.439989+00:00","generated_at":"2026-06-11T21:33:54.350080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Omeros Q2 2023 net loss $37.3M ($0.59/share); cash $341M; narsoplimab BLA path set","bullets":["Net loss Q2 2023 $37.3M vs $30.8M prior year; six-month loss $71.0M; cash burn $30.1M.","OMIDRIA royalties $10.7M on Rayner sales $35.7M; rate cut from 50% to 30% after $200M milestone.","Cash, equivalents, and short-term investments $341.3M; accounts receivable $11.2M; runway into 2025.","FDA Type B meeting; plan to submit detailed survival data analysis for narsoplimab BLA in TA-TMA; target mid-2024 decision.","Phase 3 ARTEMIS-IGAN IgA nephropathy 9-month data expected later Q3 2023; OMS906 PNH trial shows positive interim results."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014088","json":"https://secwatch.observer/filing/0001558370-23-014088.json","markdown":"https://secwatch.observer/filing/0001558370-23-014088.md","text":"https://secwatch.observer/filing/0001558370-23-014088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023014088/0001558370-23-014088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023014088/omer-20230809x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:33:54.350080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f48aef42d3a9a0514e44dc684b4e7115570657e","claim":"OMEROS CORP reported second quarter ended June 30, 2023 results: net income Net loss was $37.3 million in the quarter ended June 30, 2023, or $0.59 per share.","evidence_excerpt":"Net loss was $37.3 million in the quarter ended June 30, 2023, or $0.59 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023014088/0001558370-23-014088-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $37.3 million in the quarter ended June 30, 2023, or $0.59 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ecb5f4251e8f8de82564261c74e48f8beddde499","claim":"OMEROS CORP reported six months ended June 30, 2023 results: net income For the six months ended June 30, 2023 our net loss was $71.0 million, or $1.13 per share.","evidence_excerpt":"For the six months ended June 30, 2023 our net loss was $71.0 million, or $1.13 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023014088/0001558370-23-014088-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Net income","value":"For the six months ended June 30, 2023 our net loss was $71.0 million, or $1.13 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}